Anti-VEGF therapy

Renal cell carcinoma ( RCC ) accounts for approximately 330,000 cases diagnosed each year and 140,000 deaths worldwide. Most cases are...


A single-practice retrospective chart review has reported on long-term visual outcomes in patients receiving continuous fixed-interval dosing of anti-vascular endothelial...


Scientific literature suggests a potential association between vascular endothelial growth factor ( VEGF ) receptor inhibition and thrombotic microangiopathy (...


Bayer HealthCare has announced that the European Commission has approved Stivarga ( Regorafenib ) tablets for the treatment of adult...


In patients with KRAS, wild-type metastatic colorectal cancer ( mCRC ) a head to head comparison of anti-EGFR- and anti-VEGF-directed...


PAVES ( Pegfilgrastim and Anti-VEGF Evaluation Study ) trial has evaluated Pegfilgrastim ( Neulasta ) in 845 patients receiving FOLFOX...


The results from PAVES ( Pegfilgrastim and Anti-VEGF Evaluation Study ), a Phase 3 trial which evaluated Neulasta ( Pegfilgrastim...


Bayer HealthCare has announced that the Food and Drug Administration ( FDA ) approved Stivarga ( Regorafenib ) tablets for...


Genetic variations ensure that no two people are exactly alike, nor are their cancers. Researchers now have the tools and...


The beneficial effects of anti-angiogenesis drugs in the treatment of the deadly brain tumors called glioblastomas appear to result primarily...


Chemotherapy given in low, frequent doses – a novel strategy called "metronomic" delivery – achieved partial shrinkage of disease in...


Imaging data from a Phase 2 study of Pegaptanib ( Macugen ) in diabetic macular edema (...